BCMA CAR-T therapy combined with pomalidomide is a safe and effective treatment for relapsed/refractory multiple myeloma

被引：0
|
作者：
Yuhan Yan [1 ]
Yixuan Tu [1 ]
Qian Cheng [1 ]
Jian Zhang [1 ]
Erhua Wang [1 ]
Zuqun Deng [1 ]
Yan Yu [1 ]
Liwen Wang [1 ]
Rui Liu [1 ]
Ling Chu [2 ]
Liqing Kang [3 ]
Jing Liu [1 ]
Xin Li [1 ]
机构：
[1] The Third Xiangya Hospital,Department of Hematology
[2] Central South University,Department of Pathology
[3] The Third Xiangya Hospital,undefined
[4] Central South University,undefined
[5] Shanghai Unicar-Therapy Bio-Medicine Technology Co,undefined
来源：
Journal of Translational Medicine | / 22卷 / 1期
关键词：
Relapsed/Refractory multiple myeloma (R/R MM); BCMA CAR T-cell therapy; Pomalidomide; Combination therapy;
D O I：
10.1186/s12967-024-05772-w
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Clinical Outcomes and Salvage Therapies in Patients with Relapsed/Refractory Multiple Myeloma Following Progression on BCMA-Targeted CAR-T Therapy
    Reyes, Kevin R.
    Liu, Yen-Chun
    Huang, Chiung-Yu
    Banerjee, Rahul
    Martin, Thomas
    Shah, Nina
    Wong, Sandy W.
    Wolf, Jeffrey L.
    Arora, Shagun
    Chung, Alfred
    BLOOD, 2022, 140
  • [32] Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond
    Christopher T. Su
    J. Christine Ye
    Journal of Hematology & Oncology, 14
  • [33] Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond
    Su, Christopher T.
    Ye, J. Christine
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2021, 14 (01)
  • [34] Lenalidomide enhances the efficacy of anti-BCMA CAR-T treatment in relapsed/refractory multiple myeloma: a case report and revies of the literature
    Guoxing Zhao
    Runhong Wei
    Lei Feng
    Yi Wu
    Feng He
    Mingxing Xiao
    Zhi Cheng
    Cancer Immunology, Immunotherapy, 2022, 71 : 39 - 44
  • [35] Lenalidomide enhances the efficacy of anti-BCMA CAR-T treatment in relapsed/refractory multiple myeloma: a case report and revies of the literature
    Zhao, Guoxing
    Wei, Runhong
    Feng, Lei
    Wu, Yi
    He, Feng
    Xiao, Mingxing
    Cheng, Zhi
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (01) : 39 - 44
  • [36] CAR-T cell therapy for relapsed or refractory multiple myeloma in 2024—clinically available treatment options in Austria
    Irene Strassl
    memo - Magazine of European Medical Oncology, 2024, 17 (4) : 242 - 246
  • [37] Salvage therapies and clinical outcomes after relapse following BCMA CAR-T in patients with relapsed/refractory multiple myeloma
    Reyes, Kevin
    Liu, Yen-Chun
    Huang, Chiung-Yu
    Banerjee, Rahul
    Martin, Thomas
    Shah, Nina
    Wong, Sandy
    Wolf, Jeffrey
    Arora, Shagun
    Chung, Alfred
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S31 - S32
  • [38] High Activation of BCMA CAR-T Cells Contributes to Increased Response Rate for Patients With Relapsed/Refractory Multiple Myeloma
    Hu, Yongxian
    Zhao, Houli
    Chang, Alex Hongsheng
    Nagler, Arnon
    Huang, He
    BONE MARROW TRANSPLANTATION, 2020, 55 (SUPPL 1) : 51 - 51
  • [39] Safety and Efficacy of Anti-Bcma CAR-T Cells for Relapsed/Refractory Multiple Myeloma: A Systematic Review of Literature
    Khan, Israr
    Rafae, Abdul
    Javaid, Anum
    Ahmed, Zahoor
    Qadeer, Haifza Abeera
    Khan, Sana Irfan
    Dar, Abdul Jabbar
    Khurshid, Qasim
    Jaan, Ali
    Khalid, Farhan
    Aijaz, Zobia
    Hashmi, Mydah Sajid
    Malik, Mustafa Nadeem
    Anwer, Faiz
    BLOOD, 2020, 136
  • [40] Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma
    Saldarriaga, Mateo Mejia
    Pan, Darren
    Unkenholz, Caitlin
    Mouhieddine, Tarek H.
    Velez-Hernandez, Juan Esteban
    Engles, Katherine
    Fein, Joshua A.
    Monge, Jorge
    Rosenbaum, Cara
    Pearse, Roger
    Jayabalan, David
    Gordillo, Christian
    Chan, Hei Ton
    Yamshon, Samuel
    Thibaud, Santiago
    Mapara, Markus
    Inghirami, Giorgio
    Lentzsch, Suzanne
    Reshef, Ran
    Rossi, Adriana
    Parekh, Samir
    Jagannath, Sundar
    Richard, Shambavi
    Niesvizky, Ruben
    Bustoros, Mark
    BLOOD ADVANCES, 2024, 8 (15) : 3859 - 3869
12345